NCHR’s Public Comments on the USPSTF’s Draft Recommendation Statement for Ovarian Cancer Screening

August 10, 2017. We strongly support the USPSTF’s draft recommendation to maintain the “D” grade for ovarian cancer screening, as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. As more high-quality research becomes available, we encourage the provision of additional recommendations about the benefits and harms of using new screening strategies in asymptomatic women who are not known to be at increased risk for ovarian cancer.

Read More »

NCHR’s Public Comments on the USPSTF’s Draft Research Plan for Hepatitis B Virus Infection Screening in Pregnant Women

August 9, 2017. We support the USPSTF’s draft recommendation for Hepatitis B screening in pregnant women. Universal screening and prevention programs for pregnant women with Hepatitis B can help to identify pregnant women who are at risk for passing the virus to their children. Preventing vertical transmission protects children from a potentially serious disease and other diseases that may develop as a result, such as cancer; protects others who may be infected; and allows children to participate in school and play activities important to their healthy development. Therefore, screening is highly beneficial for these children.

Read More »

Nonprofit Groups’ Letter to Commissioner Gottlieb on Menu Labeling

August 2, 2017. The FDA should maintain the current menu labeling requirements that allow Americans to easily access nutritional information about the food they purchase. Two thirds of adults and one third of children are overweight or obese and displaying nutrition information can help them make informed decisions.

Read More »

NCHR Testimony at the FDA about Hepatitis B Vaccine, Heplisav-B

We feel for the company because it has previously tried and failed to obtain approval. However, the bottom line is we don’t know how safe the vaccine is overall, and specifically how safe it is for Asians, who comprise the majority of patients living with chronic Hepatitis B. It is better for FDA to be cautious rather than approve a potentially dangerous vaccine – especially because other options are available. We strongly urge this Advisory Committee to prioritize patient safety and urge the FDA to maintain its scientific safety standards for approval and therefore recommend additional pre-licensure studies to further evaluate the safety of Heplisav-B in subpopulations who are disproportionately affected by both acute and chronic hepatitis-B infection.

Read More »
Page 1 of 8312345...102030...Last »